Clark Square Capital
· Clark Square Capital's Ultimate Value
· April 18, 2026 at 16:06
· ⏱ 1 min read
| Read on Substack ↗
Summary
The author introduces a potential investment idea in a company that is both experiencing an operational inflection and is a beneficiary of the GLP-1 drug trend. The thesis is supported by the company's strong balance sheet, with nearly half of its market capitalization in net cash, and improving fundamentals.
•The article focuses on a company at an operational inflection point.
•The company is also identified as a winner in the GLP-1 theme.
•The investment case is supported by a strong balance sheet, with significant net cash.
•The company's fundamentals are described as improving or 'inflecting'.